Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RAK ICC Provides Strategic Solutions for Holding Companies and Regional Expansion7.1.2026 13:35:00 CET | Press release
Focused on Stability, Regulatory Alignment, and Long-Term Business Growth RAS AL KHAIMAH, UAE / ACCESS Newswire / January 7, 2026 / As businesses face increasing regulatory complexity across borders, RAK ICC offers flexible solutions to simplify expansion and protect assets. RAK ICC offers a straightforward and globally aligned registration of holding companies for high net worth individuals, families and their advisors looking to manage investments, shareholding structures, and regional expansion. With a focus on regulatory compliance and operational efficiency, RAK ICC provides businesses with the tools needed to scale within the UAE and across the region. In an ever-changing global business landscape, RAK ICC allows businesses to operate within the UAE's well-established economic and legal frameworks, ensuring they meet both local and international standards while managing operations effectively. Key Features of RAK ICC's Platform: Streamlined Business Management: RAK ICC makes it e
Datavault AI Announces Experiential Marketing Collaboration with New York’s Fifth Avenue Luxury Retailer Riflessi to Enable Sponsored Immersive 3D Digital Twins of Inventory with ADIO(R) and DVHOLO(TM)7.1.2026 13:00:00 CET | Press release
Riflessi to Deploy Digital Twins of Luxury Fashion Lines of Brunello Cucinelli, Gucci, Tom Ford, Kiton and Tommy Hilfiger® among other Leading Brands with Interactive DVHOLO 3D Holographic Display in New York's Fifth Avenue Fashion District PHILADELPHIA, PA AND NEW YORK, NY / ACCESS Newswire / January 7, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data experience, valuation, and monetization technologies, today announced a collaboration with Riflessi, a premium Fifth Avenue retail destination in New York City frequented by global consumers and internationally-recognized fashion and lifestyle labels. The collaboration is designed to install Datavault AI's DVHOLO and ADIO technology in February 2026 and aims to generate new revenue by leveraging data and content through customized displays of luxury fashion while enabling sponsored immersive advertising experiences through Datavault AI's DVHOLOTM holographic display platform and ADIO® spatial aud
A New Shade of Comfort: LiberNovo Omni Debuts New Moss Green Design6.1.2026 08:10:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / January 6, 2026 / LiberNovo The pioneer of dynamic ergonomic seating today announced the upcoming Moss Green variant of its flagship chair, the LiberNovo Omni , launching in Europe on January 17, 2026 (CET) . Building on the success of Midnight Black and Space Grey, Moss Green introduces a nature-inspired palette paired with a softer, upgraded fabric designed for long-hour comfort. As hybrid work becomes the norm across Europe, professionals increasingly seek seating that integrates seamlessly into home environments while supporting extended periods of task switching. Moss Green offers a warm, understated aesthetic that blends naturally into modern workspaces. The new colorway retains the LiberNovo Omni's full Dynamic Support system, providing adaptive support whether users are deeply focused, shifting between tasks, or relaxing after long sessions. A Calming Revival of Nature, Designed for Modern Work Inspired by forest moss, the Moss Green tone blend
Datavault AI and Available Infrastructure to Scale Physical Private Edge Cloud to Deliver Powerful Zero Trust Cybersecurity, Digital Twin and Agentic Data Monetization to 100 U.S. Cities in 20265.1.2026 14:07:00 CET | Press release
Partnership pairs Datavault AI's patented DataValue®, DataScore® and Information Data Exchange® (IDE®) solutions with Available Infrastructure's SanQtum™ cybersecure high performance points of presence designed to support near-real-time tokenization, data exchange, and agentic monetization that will provide Datavault AI the foundation to scale enterprise adoption of its AI while also solving for requisite regulatory compliance for its IDE® Quantum Key Encryption from SanQtum will further differentiate patented and forthcoming Datavault AI IDE deployments with Elements Exchange (RWA), NIL and American Political Exchanges set to Launch Q1 2026, that will be quantum ready 33 Top cities in US will begin with systems integration of patented Data Vault, DataScore, IDE and Available Infrastructure's SanQtum cybersecurity for private high performance computing in the Datavault AI Edge Network PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 5, 2026 / Datavault AI ("Datavault AI" or the "
Datavault AI and The Dream Bowl to Set New Benchmark in Sports Innovation with World’s First Tokenized Autograph Session, Featuring Current and Future NFL Stars - Live on ESPN+2.1.2026 19:50:00 CET | Press release
30 former NFL star players from different NFL Teams will autograph on-site up to 3,000 The Dream Bowl memorabilia items such as helmets, footballs, jerseys, and live-autographs by Notable Live. Autographed memorabilia items will be anchored by Prova & Sumerian technologies and digital twins will be tokenized with Data Vault. Digital tokens anchored to real The Dream Bowl autographed memorabilia items will be awarded [by lottery] to holders of the original Dream Bowl Meme Coin token (the "Dream Bowl Meme Coin I") and, following the distribution date of the Dream Bowl Meme Coin II tokens to certain record holders of Datavault AI securities as of January 7, 2026 (the "Dream Bowl Meme Coin II" and together with the Dream Bowl Meme Coin I, the "Dream Bowl Meme Coins"), to holders of the Dream Bowl Meme Coin II, throughout 2026 with an average of 10 winners selected every business day. Dream Bowl Meme Coins memorabilia digital tokens will be traded on Datavault AI's forthcoming International
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom